For example, it has been shown that, STAG2-deficient glioblastoma cells, although not STAG2-deficient Ewing sarcoma cells [24], are more responsive than STAG2 proficient cells to treatment with PARP inhibitors [25]. This evidence concerns the gene STAG2 and glioblastoma.